BIO Stock Overview
A biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
BIOTON S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | zł3.51 |
52 Week High | zł4.10 |
52 Week Low | zł3.30 |
Beta | 0.16 |
1 Month Change | -0.57% |
3 Month Change | -3.04% |
1 Year Change | -3.31% |
3 Year Change | -33.40% |
5 Year Change | -15.83% |
Change since IPO | -97.15% |
Recent News & Updates
Shareholder Returns
BIO | PL Biotechs | PL Market | |
---|---|---|---|
7D | 0.3% | -2.1% | -2.7% |
1Y | -3.3% | -18.1% | 24.5% |
Return vs Industry: BIO exceeded the Polish Biotechs industry which returned -18.1% over the past year.
Return vs Market: BIO underperformed the Polish Market which returned 24.5% over the past year.
Price Volatility
BIO volatility | |
---|---|
BIO Average Weekly Movement | 1.3% |
Biotechs Industry Average Movement | 5.7% |
Market Average Movement | 5.3% |
10% most volatile stocks in PL Market | 9.2% |
10% least volatile stocks in PL Market | 3.4% |
Stable Share Price: BIO has not had significant price volatility in the past 3 months.
Volatility Over Time: BIO's weekly volatility (1%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1989 | 357 | Jeremy Launders | www.bioton.pl |
BIOTON S.A., a biotechnology company, develops, manufactures, markets, and sells pharmaceutical ingredient and medicinal products in Poland and internationally. The company offers recombinant human insulin; oral diabetic drugs; strips for measuring sugar in blood, as well as Gensulin N, Gensulin R, and Gensulin M30; GensuPen 2, an automatic injection system; and GensuCare glucometer, a diabetes monitoring technology, as well as needles. BIOTON S.A. was founded in 1989 and is based in Ozarów Mazowiecki, Poland.
BIOTON S.A. Fundamentals Summary
BIO fundamental statistics | |
---|---|
Market cap | zł301.38m |
Earnings (TTM) | -zł2.63m |
Revenue (TTM) | zł184.75m |
1.6x
P/S Ratio-114.6x
P/E RatioIs BIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BIO income statement (TTM) | |
---|---|
Revenue | zł184.75m |
Cost of Revenue | zł120.51m |
Gross Profit | zł64.24m |
Other Expenses | zł66.87m |
Earnings | -zł2.63m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 27, 2024
Earnings per share (EPS) | -0.031 |
Gross Margin | 34.77% |
Net Profit Margin | -1.42% |
Debt/Equity Ratio | 8.1% |
How did BIO perform over the long term?
See historical performance and comparison